Soluble CXCL16 and long-term outcome in acute ischemic stroke

Atherosclerosis

Volumn 220, Issue 1, 2012, Pages 244-249

  Ueland, T ^a,c   Smedbakken, L M ^a   Hallen J ^b   Atar, D ^b,c   Januzzi, J L ^e   Halvorsen, B ^a   Jensen, J K ^d   Aukrust, P ^a,c  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

^d ODENSE UNIVERSITY HOSPITAL   (Denmark)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Acute ischemic stroke; CXCL16; Long term prognosis; Mortality

Indexed keywords

C REACTIVE PROTEIN; CXCL16 CHEMOKINE; TROPONIN;

ACUTE DISEASE; ADULT; ADVERSE OUTCOME; AGE; AGED; ARTICLE; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; FEMALE; FOLLOW UP; HEART FAILURE; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; BRAIN ISCHEMIA; CHEMOKINES, CXC; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LINEAR MODELS; MALE; MIDDLE AGED; NORWAY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RECEPTORS, SCAVENGER; RISK ASSESSMENT; RISK FACTORS; STROKE; TIME FACTORS; UP-REGULATION;

EID: 84155162476     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.10.004     Document Type: Article

References (23)

1. Brott T., Bogousslavsky J. Treatment of acute ischemic stroke. N Engl J Med 2000, 343:710-722.
2. Moser D.K., Kimble L.P., Alberts M.J., et al. Reducing delay in seeking treatment by patients with acute coronary syndrome and stroke: a scientific statement from the American Heart Association Council on cardiovascular nursing and stroke council. Circulation 2006, 114:168-182.
3. Packard R.R., Libby P. Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin Chem 2008, 54:24-38.
4. Emsley H.C., Smith C.J., Tyrrell P.J., Hopkins S.J. Inflammation in acute ischemic stroke and its relevance to stroke critical care. Neurocrit Care 2008, 9:125-138.
5. Jin R., Yang G., Li G. Inflammatory mechanisms in ischemic stroke: role of inflammatory cells. J Leukoc Biol 2010, 87:779-789.
6. Gerszten R.E., Garcia-Zepeda E.A., Lim Y.C., et al. MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions. Nature 1999, 398:718-723.
7. Shimaoka T., Kume N., Minami M., et al. Molecular cloning of a novel scavenger receptor for oxidized low density lipoprotein, SR-PSOX, on macrophages. J Biol Chem 2000, 275:40663-40666.
8. Wuttge D.M., Zhou X., Sheikine Y., et al. CXCL16/SR-PSOX is an interferon-gamma-regulated chemokine and scavenger receptor expressed in atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2004, 24:750-755.
9. Smith C., Halvorsen B., Otterdal K., et al. High levels and inflammatory effects of soluble CXC ligand 16 (CXCL16) in coronary artery disease: down-regulatory effects of statins. Cardiovasc Res 2008, 79:195-203.
10. Minami M., Kume N., Shimaoka T., et al. Expression of scavenger receptor for phosphatidylserine and oxidized lipoprotein (SR-PSOX) in human atheroma. Ann N Y Acad Sci 2001, 947:373-376.
11. Aslanian A.M., Charo I.F. Targeted disruption of the scavenger receptor and chemokine CXCL16 accelerates atherosclerosis. Circulation 2006, 114:583-590.
12. Sheikine Y., Bang C.S., Nilsson L., et al. Decreased plasma CXCL16/SR-PSOX concentration is associated with coronary artery disease. Atherosclerosis 2006, 188:462-466.
13. Lehrke M., Millington S.C., Lefterova M., et al. CXCL16 is a marker of inflammation, atherosclerosis, and acute coronary syndromes in humans. J Am Coll Cardiol 2007, 49:442-449.
14. Huang M., Han Y., Zhang X., et al. An intron polymorphism in the CXCL16 gene is associated with increased risk of coronary artery disease in Chinese Han population: a large angiography-based study. Atherosclerosis 2010, 210:160-165.
15. Wang K.D., Liu Z.Z., Wang R.M., et al. Chemokine CXC Ligand 16 serum concentration but not A181V genotype is associated with atherosclerotic stroke. Clin Chim Acta 2010, 411:1447-1451.
16. Ludwig A., Weber C. Transmembrane chemokines: versatile 'special agents' in vascular inflammation. Thromb Haemost 2007, 97:694-703.
17. Jansson A.M., Aukrust P., Ueland T., et al. Soluble CXCL16 predicts long-term mortality in acute coronary syndromes. Circulation 2009, 119:3181-3188.
18. Jensen J.K., Kristensen S.R., Bak S., Atar D., Hoilund-Carlsen P.F., Mickley H. Frequency and significance of troponin T elevation in acute ischemic stroke. Am J Cardiol 2007, 99:108-112.
19. Multicenter trial of hemodilution in ischemic stroke-background and study protocol. Scandinavian Stroke Study Group. Stroke 1985, 16:885-890.
20. Bamford J., Sandercock P., Dennis M., Burn J., Warlow C. Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet 1991, 337:1521-1526.
21. Ueland T., Dahl C.P., Gullestad L., et al. Circulating levels of non-phosphorylated undercarboxylated matrix Gla protein are associated with disease severity in patients with chronic heart failure. Clin Sci (Lond) 2011, 121:119-127.
22. Lehrke M., Konrad A., Schachinger V., et al. CXCL16 is a surrogate marker of inflammatory bowel disease. Scand J Gastroenterol 2008, 43:283-288.
23. Wu T., Xie C., Wang H.W., et al. Elevated urinary VCAM-1, P-selectin, soluble TNF receptor-1, and CXC chemokine ligand 16 in multiple murine lupus strains and human lupus nephritis. J Immunol 2007, 179:7166-7175.